NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcoma.

ABSTRACT:

Background

T-cell receptor-engineered T-cell therapies have achieved promising response rates against synovial sarcoma in clinical trials, but their applicability is limited owing to the HLA matching requirement. Chimeric antigen receptor (CAR) can redirect primary T cells to tumor-associated antigens without requiring HLA matching. However, various obstacles, including the paucity of targetable antigens, must be addressed for synovial sarcoma. Ligands for natural killer (NK) cell-activating receptors are highly expressed by tumor cells.

Methods

The surface expression of ligands for NK cell-activating receptors in synovial sarcoma cell lines was analyzed. We analyzed RNA sequencing data deposited in a public database to evaluate NKp44-ligand expression. Primary T cells retro

SUBMITTER: Murayama Y 

PROVIDER: S-EPMC9420389 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature